Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05511025 · ClinicalTrials.gov registry record · Phase 1
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT05511025 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 54 participants.
The verdict
NCT05511025, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
A study in healthy male and female participants of non-childbearing potential who are overweight or obese.
Interventions
- DRUG Placebo
- DRUG AZD6234
- COMBINATION_PRODUCT Acetaminophen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2022-09-20 |
| Est. Completion | 2023-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05511025
The ClinicalTrials.gov registry entry for NCT05511025 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05511025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05511025 about?
NCT05511025 is a clinical study titled "Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese". A study in healthy male and female participants of non-childbearing potential who are overweight or obese.
What is the current status of trial NCT05511025?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2022-09-20. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT05511025?
The interventions under investigation include: Placebo (DRUG), AZD6234 (DRUG), Acetaminophen (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05511025?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.